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Abstract
Background: Type 2 diabetes mellitus (T2DM) is a risk factor for dementia. Mild cognitive impairment (MCI), an
intermediary state between normal cognition and dementia, often occurs during the prodromal diabetic stage,
making early diagnosis and intervention of MCI very important. Latest neuroimaging techniques revealed some
underlying microstructure alterations for diabetic MCI, from certain aspects. But there still lacks an integrated
multimodal MRI system to detect early neuroimaging changes in diabetic MCI patients. Thus, we intended to
conduct a diagnostic trial using multimodal MRI techniques to detect early diabetic MCI that is determined by the
Montreal Cognitive Assessment (MoCA).
Methods: In this study, healthy controls, prodromal diabetes and diabetes subjects (53 subjects/group) aged 40-60
years will be recruited from the physical examination center of Tangdu Hospital. The neuroimaging and psychometric
measurements will be repeated at a 0.5 year-interval for 2.5 years’ follow-up. The primary outcome measures are 1)
Microstructural and functional alterations revealed with multimodal MRI scans including structure magnetic resonance
imaging (sMRI), resting state functional magnetic resonance imaging (rs-fMRI), diffusion kurtosis imaging (DKI), and
three-dimensional pseudo-continuous arterial spin labeling (3D-pCASL); 2) Cognition evaluation with MoCA. The
second outcome measures are obesity, metabolic characteristics, lifestyle and quality of life.
Discussion: The study will provide evidence for the potential use of multimodal MRI techniques with psychometric
evaluation in diagnosing MCI at prodromal diabetic stage so as to help decision making in early intervention and
improve the prognosis of T2DM.
Trial registration: This study has been registered to ClinicalTrials.gov (NCT02420470) on April 2, 2015 and published
on July 29, 2015.
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Microstructural alterations, Microvascular alterations
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Background
The prevalence of type 2 diabetes mellitus (T2DM) is
rapidly increasing, making T2DM currently a major
health challenge all over the world. Epidemiological
studies showed that the T2DM was associated with a
1.5–2.5-fold increased risk of dementia [1]. Mild cogni-
tive impairment (MCI) frequently occurs in T2DM
population at a rate of 17.2 % [2] and consequently leads
to dementia [3–5]. Moreover, MCI occurs at as early as
the prodromal diabetic stage, making the early diagnosis
of MCI an important strategy for decision making in
T2DM treatment, especially for the prevention of T2DM
related dementia.
MCI is currently diagnosed based on clinical criteria
[6], mainly the cognition evaluation, however, with bias
derived from the subjective nature of these cognition
assessing tools. Other relatively objective neuroimaging
biomarkers are proposed to detect T2DM related brain
alterations that are supposed to be the underlying mech-
anisms for MCI or dementia. T2DM related MCI may
be partly due to neuroanatomical alterations revealed by
structural magnetic resonance imaging (sMRI), including
atrophy in prefrontal cortex and the anterior cingulate
[7–9]. Findings from diffusion tensor imaging (DTI)
studies further indicated decreased fractional anisotropy
values in frontal white matter [10], cingulum bundle, un-
cinate fasciculus [11], and anterior limb of internal cap-
sule [12] in T2DM patients. Resting-state functional
magnetic resonance imaging (rs-fMRI) studies demon-
strated disrupted functional connectivity within the de-
fault mode network and decreased spontaneous brain
activity in the occipital lobe and post central gyrus in
T2DM patients [11, 13, 14]. A most recent study sug-
gested the impaired macromolecular protein pools in
fronto-striato-thalamic circuits in T2DM [15]. However,
these findings can only be detected at the late stage of
T2DM, thus cannot be used to screen MCI at the pro-
dromal diabetic stage.
Previous studies suggested that the brain microvascu-
lar alterations might explain MCI. A positron emission
tomography-computed tomography study revealed that
the focal brain blood decrease occured at as early as sev-
eral years before Alzheimer`s disease diagnosis and was
accompanied with the MCI progression [16]. On the
contrary, a trend to a slight cerebral blood flow (CBF)
increase in bilateral hippocampi and the posterior
cingulate gyrus among patients with MCI was noticed
using dynamic susceptibility contrast MRI [17]. The
major shortcoming of these methods to measure CBF is
the use of radio-labeled contrast agents, thus, not suit-
able for screening brain microvascular alterations in the
prodromal diabetic population. Three-dimensional
pseudo-continuous arterial spin labeling (3D-pCASL), a
non-invasive and non-contrast perfusion imaging
method [18], is commonly used to measure CBF alter-
ations and demonstrates equivalent diagnostic perform-
ance to Single-photon emission computed tomography
(SPECT) for Alzheimer`s disease [19].
Thus, we designed the current prospective diagnostic
trial for 2 purposes. First, to investigate the structure,
functional alterations and gray/white matter integrity
with sMRI, fMRI and diffusional kurtosis imaging (DKI,
also measures non-Gaussian diffusion and may provide
additional and complementary information to DTI [20])
in prodromal diabetic population, respectively. Second,
to investigate the early brain microvascular alterations
by using 3D-pCASL.We hope to establish an integrated
diagnosing system for early MCI in prodromal diabetic
population by using multimodal MRI techniques.
Methods/Design
The scheme of the current prospective trial is described
in Fig. 1 and the following part.
Subject
Subjects inclusion
Participants with a minimum of the senior high school
education will be prospectively recruited in one of the
three groups: healthy control (HC), prodromal diabetes,
or T2DM group according to the following inclusion cri-
teria. HC group: Individuals with normal HbA1c and
blood glucose level and no evidence of T2DM will be re-
cruited into this group. Their fasting plasma glucose
(FPG) levels are < 5.6 mmol/L, and 2 h fasting glucose
(PG) levels for oral glucose tolerance test (OGTT) are <
7.8 mmol/L. Prodromal diabetes group: Individuals who
have the impaired fasting glucose (IFG, FPG 5.6-
6.9 mmol/L) or impaired glucose tolerance (IGT, 2 h PG
for OGTT 7.8-11.1 mmol/L, but not meet the diagnostic
criteria for T2DM will be recruited in this group. T2DM
group: Individuals will be recruited into this group if
they fall in any one of the following criteria: (1) FPG ≥
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7.0 mmol/L or, (2) 2 h PG for OGTT ≥11.1 mmol/L or,
(3) random PG ≥11.1 mmol/L in the presence of typ-
ical diabetes symptoms.
Subjects exclusion
Subjects will be excluded because of any one of the fol-
lowing conditions. 1) dementia, which is defined by the
<21 score in mini-mental state examination (MMSE); 2)
obese, which is defined by the > 28 score of the body
mass index; 3) other type of diabetes, such as type 1 dia-
betes mellitus and secondary diabetes mellitus; 4) serious
brain diseases, such as significant head trauma, tumor,
meningitis or central nervous system inflammatory le-
sions and vascular complications (e.g., infarction and
encephalomalacia foci) clues which may be detected with
conventional MR scan; 5) MRI contraindications; or 6)
taking psychoactive or steroid hormones drugs during
the past 3 months.
Participants will receive laboratory, neuropsychological
tests as well as multimodal brain MRI scans during a
comprehensive 6 h evaluation completed over three
visits within 2 weeks.
Neuropsychological assessments
All individuals received the following a battery of neuro-
psychological tests within 2 weeks before imaging:
MMSE, Montreal Cognitive Assessment (MoCA),
Frontal Assessment Battery (FAB), Hamilton Anxiety
Scale (HAS), Self-Rating Depression Scale (SDS), the
World Health Organization Quality of Life assessment
(WHOQOL).
Magnetic resonance brain imaging
Imaging protocol
Imaging data will be acquired using a 3.0-T MRI system
(MR750; GE Healthcare, Milwaukee, WI, USA) using an
8-channel head coil array with foam padding to restrict
head motion. For each participant, conventional brain
T1-weighted (T1WI), T2-weighted (T2WI) and fluid-
attenuated inversion recovery (FLAIR) images will be
obtained to exclude serious brain diseases. All of the
sequences we mentioned use the isotropic spatial reso-
lution. All MR images will be assessed by two experienced
radiologists (with over 5-year experience).
sMRI
Following the pilot scan, for brain structure segmenta-
tion and image registration to a brain anatomy template,
an axial 3D brain volume imaging (3D-BRAVO) will be
acquired for T1WI, according to the following parame-
ters: echo time (TE) = 3.2 ms, repetition time (TR) =
8.2 ms, inversion time(TI) = 450 ms, flip angle (FA) =
12°, field of view (FOV) =256 × 256 mm2, matrix = 256 ×
Fig. 1 Flowchart of the current prospective diagnostic trial
Yu et al. BMC Medical Imaging  (2016) 16:50 Page 3 of 7
256, slice thickness = 1 mm, slice number = 188. The
whole procedure will cost 4 min 10 s.
3D-pCASL
According to the White Paper of the International Soci-
ety for Magnetic Resonance in Medicine (ISMRM) per-
fusion study group [21], Perfusion images will be
obtained using a 3D-pCASL technique [22] with the fol-
lowing parameters: 512 sampling points on eight spiral
arms, TR = 4886 ms (post label delay (PLD) = 2025 ms),
TE = 10.5 ms, slice number = 40, FOV = 256 × 256 mm2,
matrix = 128 × 128, slice thickness = 2.0 mm, number of
excitations (NEX) = 3, FA = 111°. The bottom of the slab
should be positioned at the bottom of the cerebellum,
with coverage of the entire cerebrum. This sequence is
pseudo-continuous labeling, background suppression,
and a segmented three-dimensional readout without vas-
cular crushing gradients. A simplified model will be used
to calculate and present both label/control difference
images and cerebral blood flow in absolute units. The
whole scan will cost 4 min.
DKI
DKI datasets will be acquired using a spin-echo single-shot
diffusion tensor echo planar imaging (SE-SS-DT-EPI) se-
quence with a clinically oriented protocol. The acquisition
parameters will include three b-values of 0, 1000, and
2000 s/mm2, 10 b0 images, 25 diffusion gradient directions,
TR/TE = 5800/77 ms, FOV =256 × 256 mm2, matrix =
128 × 128, slice thickness = 2 mm, FA = 90°, slice number =
48, in-plane spatial resolution = 2 × 2 mm2. The acquisition
time for this protocol will be 5 min 54 s.
rs-fMRI
rs-fMRI images will be collected using an EPI sequence
with the following parameters: TR = 2000 ms, TE =
30 ms, FA = 90°, slice number = 33, inter slice gaps =
0 mm, FOV = 192 × 192 mm2, matrix = 64 × 64, slice
thickness = 3 mm, in-plane spatial resolution = 3 ×
3 mm2. Participants will be asked to lie quietly in the
scanner with their eyes closed and thinking nothing dur-
ing data acquisition. The scan will last for 6 min 10 s.
MRI image analysis
sMRI data analysis
Measurements of total intracranial, whole brain and
ventricular volumes will be calculated using volumet-
ric output measures and semi-automated segmenta-
tion from FreeSurfer ASEG analysis [23]. Whole brain
and ventricular volumes will be normalized to the
whole intracranial volume to adjust for variability due
to head size. The normalized volumes were used for
among group comparisons to evaluate the significant
group differences.
3D-pCASL data analysis
Data will be preprocessed using Statistical parametric
mapping (SPM12) (http://www.fil.ion.ucl.ac.uk/spm/soft-
ware/spm12/), in which 3D-BRAVO and 3D-pCASL im-
ages will be corrected for gradient nonlinearities in all
directions. Realignment, coregistration and segmentation
will be included in the preprocessing. ASL images will
be registered to the brain extracted from the 3D-
BRAVO. Mean whole-brain CBF values will be calcu-
lated in the mask, converted to quantitative CBF maps
with the unit of mL/100 g/min. And then it will be nor-
malized to Montreal Neurological Institute (MNI) space
with a 3-mm isotropic resolution, and smooth with an
isotropic kernel of 8 mm. Multiple comparisons correc-
tion will be used (P < 0.05) to investigate voxel-wise CBF
differences among groups with a minimum size of
50 pixels. All results will be expressed in the MNI space.
Mean regional CBF values will be measured in each
interested gyri.
DKI data analysis
Data will be processed using a combination of in-house
image processing tools developed in MATrix LABora-
tory(MATLAB) (Mathworks, Natick, USA) and tools
available as part of Freesurfer (http://surfer.nmr.mgh.har-
vard.edu) and FMRIB’s Software Library (FSL FSLversion 5.0,
http://www.fmrib.ox.ac.uk/fsl). The diffusion dataset will be
corrected to get potential 3D head motion and eddy current
distortion using FSL eddy correct. The toolbox imple-
mented in MATLAB will be used to deal with diffusional
kurtosis tensors [24]. Coefficients from these tensors will
be estimated for each voxel using a previously de-
scribed homogenous polynomials approach, in which
positive diffusivity function, positive-definite estimated
diffusion tensor, and constrained estimated apparent kur-
tosis will be done [24, 25].
rs-fMRI
rs-MRI imaging data will be preprocessed in the toolbox
of MATLAB R2012b Data Processing Assistant for
Resting-State fMRI (DPARSF, http://www.restfmri.net/
forum/DPARSF), SPM12 and rs-fMRI data analysis tool-
kit (REST1.8; http://www.restfmri.net) will be selected to
deal with the images. Slice timing and realignment for
head motion correction will be performed. Any images
with head motion 3.0-mm translation or 3.0° rotation in
any direction will be excluded. Amplitude of low fre-
quency fluctuation (ALFF) and regional homogeneity
(ReHo) images will be estimated in the REST software as
described in previous studies [26, 27]. For ALFF and
ReHo analysis, the resampled images will be smoothed,
linear trend and band-pass filtering (0.01–0.08 Hz). All
the results will be expressed in the MNI space, and the
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data can be read and described through the REST
software.
Functional connectivity among groups is also from the
rs-MRI imaging data. Data analysis will be carried out
using MELODIC of FSL. Images will firstly be slice-time
and motion corrected followed by normalization and
spatial smoothing. The number of components is fixed
at 20 [28]. The group ICA was repeated several times
using unique randomly resampled data to ensure stabil-
ity of 20 independent components. A meta-ICA analysis
will be then carried out using all iterations of the group
ICA components to extract the 20 spatially independent
components consistently identified across the group ICA
runs. Dual regression will be applied to each individual’s
preprocessed datasets using the 20 group components.
The first regression model uses the template as a spatial
predictor for the participant’s 4D data. The second re-
gression equation estimated the individual regression
weights in the spatial domain. Individual default mode
network component maps will be selected to carry out
group-level statistics.
Follow up
A follow-up assessment will be performed within
three years after individual’s first visit with changes of
imaging presentations and other outcomes in the
three groups as time goes on (up to 36 months) be
compared. Individuals will come back to the medical
center once half a year for countercheck. All the pro-
tocols and evaluations are the same with that they get
at the first time.
Sample size calculation and statistics
Power calculations have been estimated with reference
to other studies that used similar end points [21, 29], ac-
cording to the formula for estimating the variances of
mean values from multiple groups [29]. A sample size of
40 patients per group will be suitable with a power of
0.8, an alpha significance level of 0.05 (two-side). In our
group, longitudinal changes of this effect size have been
shown previously in groups larger than 10 subjects.
Given a drop-out ratio of included subjects, at 25 %, into
account, the total sample size is 53 in each group.
Demographic clinical, laboratory, cognitive, and neuro-
psychological data will be analyzed using SPSS 22.0
(SPSS, Inc.). One-way analysis of variance or χ2 test will
be used to explore differences of these data among three
groups (HC, prodromal diabetes and diabetes). Neuro-
psychological difference among them will be performed
with analysis of covariance (ANCOVA) using demo-
graphic factors (gender, age, and years of education) as
covariates. Post-hoc comparisons will then be performed
with all demographic factors (gender, age, and years of
education) as covariates. P < 0.05 is considered as
significant. It is reported ReHo and ALFF values are af-
fected by the structure alterations (e.g., atrophy) [30].
We will take ventricular volume as a covariance to rule
out such influence.
For images analysis, one-sample t tests will be per-
formed on the individual corresponding maps for each
group using SPM12 to explore the differences within
groups. Dunnett-t test will be performed for differ-
ences among case groups and healthy control group.
The statistical threshold of the two test will both be set at
P <0.005 which corresponded to a corrected P <0.005
(multiple comparisons with family-wise error).
Linear regression analysis is performed across the
T2DM groups and prediabetes groups to assess relation-
ships between imaging values and cognitive testing
scores. When the most sensitive parameters are found, a
receiver operating characteristic (ROC) curve will be
generated to achieve the sensitivity and specificity of the
certain parameter for early detection of the cognitive
decline.
Primary outcome measure
1) Network connectivity among multiple brain regions
and neuroimaging biomarkers with the 2.5 years’
follow-up at 0.5 year interval. [Time Frame: subjects
will be assessed six times (once half a year, up to
2.5 years)]
2) Differences in macro-structural and micro-structural
network connectivity among healthy controls, pro-
dromal diabetes and diabetes will be evaluated.
These MRI measures include volumetric characteris-
tics (e.g., hyper-intensities, white matter lesions,
atrophy), quantitative measures (e.g., T2 relaxation
times, mean diffusivity, fractional anisotropy, mean
kurtosis), functional characteristics (e.g., activated
regions, cerebral blood flow), network properties
(e.g., functional and structural connectivity, graph-
theoretical measures). [Time Frame: subjects will be
assessed six times (once half a year, up to 2.5 years)]
Secondary outcome measures
1) Evaluation of obesity and the changes in the state of
obesity at 2.5 years. Simple evaluation of obesity will
include: body mass index will be calculated as the
weight (kg) divided by the square of the height (m2).
Waist circumference will be taken as the minimum
circumference between the umbilicus and xiphoid
process and measured to the nearest 0.5 cm. [Time
Frame: subjects will be assessed six times (once half
a year, up to 2.5 years)]
2) Metabolic characteristics and their changes at
2.5 years. Simple metabolic characteristics will
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include: oral glucose tolerance test, C peptide
releasing test and insulin releasing test, homeostasis
model assessment of insulin resistance,insulin
secretion of homeostasis model assessment and
homeostasis model assessment-β. What’s more,
cardiovascular risk factors (e.g., albumin, creatinine,
total cholesterol, low density lipoprotein (LDL)- and
high density lipoprotein (HDL)-cholesterol, triglycer-
ides, glycosylated hemoglobin) will be assessed.
[Time Frame: subjects will be assessed six times
(once half a year, up to 2.5 years)]
3) Mental health and the changes in the scores of the
scales at 2.5 years. To evaluate the mental health, a
series of psychiatric evaluation scale (e.g., MMSE,
MoCA,HAS, SDS, WHOQOL) will be assessed.
[Time Frame: subjects will be assessed six times
(once half a year, up to 2.5 years)]
4) Lifestyle and its changes at 2.5 years. Lifestyle specifics,
including alcohol consumption, smoking behavior and
mobility and exercise habit will be obtained. At the
same time, quality of life will be obtained through a
questionnaire. [Time Frame: subjects will be assessed
six times (once half a year, up to 2.5 years)]
Discussion
The current study evaluates various characteristics of
diabetes, especially the central nervous system image
presentations in different stage of diabetes progression,
and aims to establish an imaging evaluation system for
detecting and evaluate MCI in diabetes. Benefits and
limitations of this study are discussed below.
It is reported by most researchers that diabetes result in
regional hypoperfusion. However, Henry Rusinek and his
colleagues found that no hypoperfusion exists in diabetes
group, in contrast to hypoperfusion in insulin resistant but
not diabetes group [29]. Since insulin resistant is one of
main mechanisms of diabetes, we are still uncertain why
the perfusion data differs between the two groups. The
current study will follow up individual’s characteristics in
various areas, especially the image presentation for not
less than 3 years. Natural progression of diabetes is moni-
tored. Reperfusion or compensation result in diabetes will
be explored. We may discovery the unrevealed mechanism
for the divergent between IR and diabetes group.
Structure changes are common in advanced T2DM. It
may also exist at prediabetes stage. The volume changes
should be used to be one of the covariant to prevent its
effect to signal intensity. In current study, we take cere-
bral ventricle volume, which may represent the structure
changes of the whole brain, as a covariant. DKI reveals
the non-Gaussian characteristics of gray and white mat-
ter [31]. Imaging reports of this respect in diabetes are
limited. We undergo the examination of DKI, instead of
DTI to explore the real world of microstructure.
Various imaging researches of diabetes have been re-
ported. Most of them are studies of one or two proto-
cols. In our study, multi-modal sequences will be
conducted and analyzed at the same time. It may be re-
vealed which one or combined protocols may express
the highest area under curve by drawing ROC curve.
Corresponding sensitivity and specificity are calculated,
and then we will get the cutoff values to diagnose MCI.
MoCA is verified to be a valid scale for MCI in diabetes
in China [32]. Different dimensions scores of MoCA will
be calculated and analyzed together with imaging presen-
tations. Therefore, we may detect the functional node for
different cognitive dimensions. The association may help
to speculate prognosis. The neuropsychological test bat-
tery comprises another four scales. They test the condition
of cognition, affection and life style. Different cognitive-
related circuits overlap and interact significantly. There-
fore, affective and life style state evaluation is necessary
for matching the changes of cerebral functional imaging
presentations.
Treatment strategies vary significantly. According to
our preliminary experiment, patients took metformin ei-
ther alone or in combination with other drugs. Some of
the diabetes went on insulin treatment. Part of the predia-
betes group took statin-related drugs. Antihypertensive
drugs were also taken by some individuals to control their
blood pressure. Medications related to cardiovascular dis-
ease affect cerebral perfusion significantly [27], and they
may play a role in neuronal plasticity as well [26]. In the
current study, we have not taken medication therapies as
covariant for some practice and ethics issues. The re-
liability of results may be affected by the disaccord of
medication therapies.
Future studies should focus on comparing the imaging
characteristics between MCI converted group and no
converted group. Gene type may serve as a control con-
dition. Other techniques such as using MRS for the
metabolic data could be useful and should be evaluated
as well. The consistency of therapeutic regimen should
also be guaranteed.
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